TrialCancer research and treatment2022

Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study.

Joonha Kwon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.